Drugs / ChAd155-RSV
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03636906 | Apr 2019 → Jan 2020 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT02927873 | Jan 2017 → Feb 2019 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAd155-RSV | “This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1),...” PMID 36484484 ↗ May 20231“an investigational chimpanzee-derived adenoviral vector RSV vaccine (ChAd155-RSV, expressing RSV F, N, and M2-1) in infants.” PMID 37477875 ↗ Jan 2024 |
| Known as | GSK3389245A | “GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants” NCT02927873 ↗ |
| Modality | Vaccine | “ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins” PMID 36484484 ↗ May 2023 |
| Route | Intramuscular | “when first administered via intramuscular (IM) injection according to a 0, 1-month schedule” NCT02927873 ↗ |